Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather Landau

Showing results (51-60 of 99) with videos related to

Pageof 10
Sort By:
JACC. Cardiovascular Imaging|December 19, 2021
Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful TherapySarah A M Cuddy, Michael Jerosch-Herold, Rodney H Falk, et al.
Research Square|March 3, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple MyelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 7, 2019
Quantitative [<sup>18</sup>F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosisYiu Ming Khor, Sarah Cuddy, Hendrik J Harms, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 1, 2020
Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaMeghan Salcedo, Nikoletta Lendvai, Donna Mastey, et al.
Blood Advances|May 4, 2022
Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myelomaAnkit Kansagra, Angela Dispenzieri, Raphael Fraser, et al.
Transplantation and Cellular Therapy|December 19, 2024
Health-Related Values Discussions with Patients Undergoing Allogeneic and Autologous Stem Cell Transplant: Feasibility and Acceptability of an Early Primary Palliative Care InterventionAbigail G Cohen, Christina Cho, Emily Patterson, et al.
Leukemia & Lymphoma|January 9, 2018
Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicityNikoletta Lendvai, Ioanna Tsakos, Sean M Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 31, 2017
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide MaintenanceMeighan Palazzo, Gunjan L Shah, Olivia Copelan, et al.
American Journal of Hematology|April 11, 2025
The Impact of Melphalan Conditioning and CD34 <sup>+</sup> Cell Dose and Schedule on Post-Transplant Outcomes in AL AmyloidosisEli Muchtar, Vaishali Sanchorawala, Hamza Hassan, et al.
Blood Cancer Journal|August 18, 2022
Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research GroupAndrea Havasi, Cihan Heybeli, Nelson Leung, et al.
Pageof 10

Showing results (51-60 of 99) with videos related to

Sort By:
Pageof 10
JACC. Cardiovascular Imaging|December 19, 2021
Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful TherapySarah A M Cuddy, Michael Jerosch-Herold, Rodney H Falk, et al.
Research Square|March 3, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple MyelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 7, 2019
Quantitative [<sup>18</sup>F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosisYiu Ming Khor, Sarah Cuddy, Hendrik J Harms, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 1, 2020
Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaMeghan Salcedo, Nikoletta Lendvai, Donna Mastey, et al.
Blood Advances|May 4, 2022
Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myelomaAnkit Kansagra, Angela Dispenzieri, Raphael Fraser, et al.
Transplantation and Cellular Therapy|December 19, 2024
Health-Related Values Discussions with Patients Undergoing Allogeneic and Autologous Stem Cell Transplant: Feasibility and Acceptability of an Early Primary Palliative Care InterventionAbigail G Cohen, Christina Cho, Emily Patterson, et al.
Leukemia & Lymphoma|January 9, 2018
Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicityNikoletta Lendvai, Ioanna Tsakos, Sean M Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 31, 2017
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide MaintenanceMeighan Palazzo, Gunjan L Shah, Olivia Copelan, et al.
American Journal of Hematology|April 11, 2025
The Impact of Melphalan Conditioning and CD34 <sup>+</sup> Cell Dose and Schedule on Post-Transplant Outcomes in AL AmyloidosisEli Muchtar, Vaishali Sanchorawala, Hamza Hassan, et al.
Blood Cancer Journal|August 18, 2022
Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research GroupAndrea Havasi, Cihan Heybeli, Nelson Leung, et al.
Pageof 10